Alerts will be sent to your verified email
Verify EmailTORNTPHARM
|
Torrent Pharma
|
Cipla
|
Dr. Reddy's Lab
|
|
|---|---|---|---|
|
Operational Metrics
|
|||
|
Pharmaceuticals
|
|||
|
Number of ANDA's Filed in USA
|
172.0 . | 285.0 . | 367.0 . |
|
Number of ANDA's Approved By USFDA
|
132.0 . | 225.0 . | 294.0 . |
|
Domestic Sales Growth - YoY
|
12.3 % | 6.8 % | 9.1 % |
|
R&D as a % of Total Sales
|
5.0 % | 7.1 % | 7.0 % |
|
Financials
|
|||
|
5 yr Average ROE
|
20.79 % | 13.9 % | 15.68 % |
|
5yr average Equity Multiplier
|
2.16 | 1.25 | 1.41 |
|
5yr Average Asset Turnover Ratio
|
0.69 | 0.78 | 0.74 |
|
5yr Avg Net Profit Margin
|
13.95 % | 14.31 % | 15.18 % |
|
Price to Book
|
15.19 | 3.65 | 2.9 |
|
P/E
|
59.98 | 22.11 | 18.09 |
|
5yr Avg Cash Conversion Cycle
|
-186.79 Days | -4.31 Days | 74.48 Days |
|
Inventory Days
|
54.98 Days | 57.83 Days | 76.14 Days |
|
Days Receivable
|
40.18 Days | 50.64 Days | 95.44 Days |
|
Days Payable
|
298.32 Days | 105.99 Days | 102.6 Days |
|
5yr Average Interest Coverage Ratio
|
7.38 | 53.73 | 35.66 |
|
5yr Avg ROCE
|
25.78 % | 19.36 % | 21.82 % |
|
5yr Avg Operating Profit Margin
|
30.49 % | 23.02 % | 23.61 % |
|
5 yr average Debt to Equity
|
0.66 | 0.03 | 0.12 |
|
5yr CAGR Net Profit
|
8.83 % | 17.0 % | 23.71 % |
|
5yr Average Return on Assets
|
9.73 % | 11.19 % | 11.24 % |
|
Shareholdings
|
|||
|
Promoter Holding
|
68.31 % | 29.21 % | 26.64 % |
|
Share Pledged by Promoters
|
0.0 | 0.0 | 0.0 |
|
Change in Promoter Holding (3 Yrs)
|
-2.94 % | -4.4 % | -0.07 % |
|
Change in Mutual Fund Holding (3 Yrs)
|
-1.6 % | 6.45 % | 0.47 % |
|
Torrent Pharma
|
Cipla
|
Dr. Reddy's Lab
|
|
|---|---|---|---|
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
Product Wise Break-Up
|
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
|
Acute vs Chronic
|
Acute vs Chronic
|
-
|
-
|
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
Therapeutic Area Break-Up
|
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|
Asset Break-Up
|